European Neural Implants Market 2025-2035

Description

List of Tables

European Neural Implants Market Size, Share & Trends Analysis Report by Product (Deep Brain Stimulation (DCS), Spinal Cord Stimulation (SCS), and Vagus Nerve Stimulation (VNS)), by Application (Chronic Pain, Epilepsy, Parkinson's Disease (PD), and Others (Depression and Other Movement Disorders)), and by End-user (Hospitals, Outpatient Surgery Centers, and Specialized Neurological Centers (SNCs)), Forecast Period (2025-2035)

Industry Overview

European neural implants market was valued at $1.89 billion in 2024 and is projected to reach $6.28 billion by 2035, growing at a CAGR of 11.5% during the forecast period (2025-2035). The European neural implants market is driven by advancements in neurostimulation therapies and innovative implantable devices. The increasing prevalence of neurological disorders, including Parkinson's disease and chronic pain, has amplified demand for targeted treatment solutions. Companies such as Boston Scientific and Medtronic plc are introducing next-generation neural implants with enhanced precision and programmability, improving clinical outcomes. Favorable healthcare policies and reimbursement frameworks across key European countries are supporting wider adoption. Additionally, ongoing research collaborations and clinical trials are accelerating the development of safer, minimally invasive procedures.

Market Dynamics

Rising Adoption of Deep Brain Stimulation (DBS) for Neurological Disorders

The European neural implants market is witnessing significant growth due to increasing adoption of Deep Brain Stimulation (DBS) for treating movement disorders such as Parkinson's disease. Companies such as Medtronic plc have introduced advanced DBS systems, enabling precise stimulation and improved patient outcomes. Enhanced clinical awareness and favorable reimbursement policies across countries such as Germany and France are further supporting market expansion. Research initiatives focusing on neurodegenerative disease therapies also drive demand for innovative implants. Hospitals and specialized neurology centers remain the primary end-users of these devices.

Expansion of Spinal Cord Stimulation (SCS) for Chronic Pain Management

Spinal Cord Stimulation (SCS) is gaining traction in Europe as an effective solution for managing chronic pain conditions. Abbott Laboratories has introduced next-generation SCS devices with improved battery life and programming flexibility, enhancing patient compliance. The growing prevalence of chronic pain and advancements in minimally invasive implant procedures are boosting market adoption. Countries with established healthcare infrastructure, including the UK and Italy, show strong demand for SCS therapies. Additionally, collaborative efforts between medical device manufacturers and research institutions are fostering innovation.

Market Segmentation

Based on the product, the market is segmented into deep brain stimulation (DCS), spinal cord Stimulation (SCS), and vagus nerve stimulation (VNS).
Based on the application, the market is segmented into chronic pain, epilepsy, Parkinson's Disease (PD), and Others (depression and other movement disorders).
Based on the end-user, the market is segmented into hospitals, outpatient surgery centers, and specialized neurological centers (SNCs).

Deep Brain Stimulation (DBS) Segment to Lead the Market with the Largest Share

The European neural implants market is expanding steadily, owing to the rising use of Deep Brain Stimulation (DBS) in treating movement disorders. Medtronic plc has introduced advanced DBS systems that allow customizable stimulation, enhancing patient mobility and quality of life. Increasing clinical adoption in neurology centers across France, Germany, and the UK supports market momentum. Continuous technological improvements, including rechargeable and MRI-compatible devices, further stimulate demand. Government-backed healthcare initiatives and reimbursement schemes are facilitating broader access to these therapies.

Parkinson's Disease (PD): A Key Segment in Market Growth

The prevalence of Parkinson's Disease (PD) is significantly contributing to the growth of the European neural implants market. Boston Scientific offers specialized implantable devices designed to alleviate motor symptoms and improve long-term patient outcomes. Increased awareness among neurologists and patients about advanced neuromodulation options is encouraging adoption. Clinical studies demonstrating improved efficacy of these devices further support market confidence. Healthcare infrastructure in countries such as Germany, Italy, and Spain enables efficient deployment of PD-targeted implants.

Regional Outlook

The Europe neural implants market is further divided by countries, including Germany, the UK, France, Spain, Italy, Russia, and the Rest of Europe.

Germany Dominates the Market with a Major Share

The neural implants market in Germany is experiencing rapid growth owing to rising demand for advanced neuromodulation therapies and minimally invasive surgical solutions. Abbott Laboratories has launched innovative spinal cord and brain stimulation devices, improving pain management and neurological treatment outcomes. The country's robust healthcare system and strong clinical research environment support accelerated adoption of new technologies. Favorable reimbursement policies and an increasing number of specialized neurology centers contribute to market expansion. Additionally, ongoing collaborations between medical device companies and research institutions drive continuous innovation.

Market Players Outlook

The major companies operating in the Europe neural implants market include CorTec GmbH, Aleva Neurotherapeutics SA, Neuro France Implants, NeuroPace Inc., LivaNova PLC, and others. The companies are pursuing partnerships, collaborations, mergers, and acquisitions to drive innovation, expand product portfolios, enhance sustainability, and strengthen market presence. These strategies enable players to respond to growing demand for energy-efficient, high-performance insulation solutions across residential, commercial, and industrial applications while maintaining a competitive edge.

Recent Developments

In July 2025, CorTec GmbH, a pioneer in active implantable medical technologies, announced the first human implantation of its proprietary BCI system, Brain Interchange, marking a pivotal advance in translating laboratory research into clinical applications. This novel approach offers highly precise and personalized treatment for neurological conditions. The implant system continuously records brain activity, instantly interpreting signals and delivering targeted electrical stimulation in real time to enhance neuroplasticity, the brain's ability to reorganize neural networks.
In July 2025, Newcastle was selected as one of two sites in the UK to look at how a new brain implant could help improve the quality of life, mobility, and independence in severely paralysed patients. The feasibility study, involving Newcastle University, aims to evaluate the safety and functionality of an implant called N1, produced by medical technology company Neuralink. The wireless brain-computer interface (BCI) is an implant designed to enable voluntary control of external devices, such as a computer or mobile phone, using brain activity.

The Report Covers:

Market value data analysis of 2024 and forecast to 2035.
Annualized market revenues ($ million) for each market segment.
Country-wise analysis of major geographical regions.
Key companies operating in the European neural implants market. Based on the availability of data, information related to new products and relevant news is also available in the report.
Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
Analysis of market-entry and market expansion strategies.
Competitive strategies by identifying 'who-stands-where' in the market.

Product Code: OMR2023489

1. Report Summary

Current Industry Analysis and Growth Potential Outlook
European Neural Implants Market Sales Analysis - Product | Application | End-User | ($ Million)
European Neural Implants Market Sales Performance of Top Countries
1.1. Research Methodology
Primary Research Approach
Secondary Research Approach
1.2. Market Snapshot

2. Market Overview and Insights

2.1. Scope of the Study
2.2. Analyst Insight & Current Market Trends
- 2.2.1. Key European Neural Implants Industry Trends
- 2.2.2. Market Recommendations

3. Market Determinants

3.1. Market Drivers
- 3.1.1. Drivers For European Neural Implants Market: Impact Analysis
3.2. Market Pain Points and Challenges
- 3.2.1. Restraints For European Neural Implants Market: Impact Analysis
3.3. Market Opportunities

4. Competitive Landscape

4.1. Competitive Dashboard - European Neural Implants Market Revenue and Share by Manufacturers
Neural Implants Product Comparison Analysis
Top Market Player Ranking Matrix
4.2. Key Company Analysis
- 4.2.1. Aleva Neurotherapeutics SA
  - 4.2.1.1. Overview
  - 4.2.1.2. Product Portfolio
  - 4.2.1.3. Financial Analysis (Subject to Data Availability)
  - 4.2.1.4. SWOT Analysis
  - 4.2.1.5. Business Strategy
- 4.2.2. CorTec GmbH
  - 4.2.2.1. Overview
  - 4.2.2.2. Product Portfolio
  - 4.2.2.3. Financial Analysis (Subject to Data Availability)
  - 4.2.2.4. SWOT Analysis
  - 4.2.2.5. Business Strategy
- 4.2.3. LivaNova PLC
  - 4.2.3.1. Overview
  - 4.2.3.2. Product Portfolio
  - 4.2.3.3. Financial Analysis (Subject to Data Availability)
  - 4.2.3.4. SWOT Analysis
  - 4.2.3.5. Business Strategy
- 4.2.4. Neuro France Implants
  - 4.2.4.1. Overview
  - 4.2.4.2. Product Portfolio
  - 4.2.4.3. Financial Analysis (Subject to Data Availability)
  - 4.2.4.4. SWOT Analysis
  - 4.2.4.5. Business Strategy
- 4.2.5. NeuroPace Inc.
  - 4.2.5.1. Overview
  - 4.2.5.2. Product Portfolio
  - 4.2.5.3. Financial Analysis (Subject to Data Availability)
  - 4.2.5.4. SWOT Analysis
  - 4.2.5.5. Business Strategy
4.3. Top Winning Strategies by Market Players
- 4.3.1. Merger and Acquisition
- 4.3.2. Product Launch
- 4.3.3. Partnership And Collaboration

5. European Neural Implants Market Sales Analysis by Product ($ Million)

5.1. Deep Brain Stimulation (DCS)
5.2. Spinal Cord Stimulation (SCS)
5.3. Vagus Nerve Stimulation (VNS)

6. European Neural Implants Market Sales Analysis by Application ($ Million)

6.1. Chronic Pain
6.2. Epilepsy
6.3. Parkinson's Disease (PD)
6.4. Others (Depression and Other Movement Disorders)

7. European Neural Implants Market Sales Analysis by End-User ($ Million)

7.1. Hospitals
7.2. Outpatient Surgery Centers
7.3. Specialized Neurological Centers (SNCs)

8. Regional Analysis

8.1. European Neural Implants Market Sales Analysis - Product | Application | End-User | Country ($ Million)
Macroeconomic Factors for European
- 8.1.1. Germany
- 8.1.2. UK
- 8.1.3. France
- 8.1.4. Spain
- 8.1.5. Italy
- 8.1.6. Spain
- 8.1.7. Russia
- 8.1.8. Rest of Europe

9. Company Profiles

9.1. Aleva Neurotherapeutics SA
- 9.1.1. Quick Facts
- 9.1.2. Company Overview
- 9.1.3. Product Portfolio
- 9.1.4. Business Strategies
9.2. ANT Neuro
- 9.2.1. Quick Facts
- 9.2.2. Company Overview
- 9.2.3. Product Portfolio
- 9.2.4. Business Strategies
9.3. BIOS Health
- 9.3.1. Quick Facts
- 9.3.2. Company Overview
- 9.3.3. Product Portfolio
- 9.3.4. Business Strategies
9.4. Blackrock Neurotech
- 9.4.1. Quick Facts
- 9.4.2. Company Overview
- 9.4.3. Product Portfolio
- 9.4.4. Business Strategies
9.5. Carthera
- 9.5.1. Quick Facts
- 9.5.2. Company Overview
- 9.5.3. Product Portfolio
- 9.5.4. Business Strategies
9.6. CorTec GmbH
- 9.6.1. Quick Facts
- 9.6.2. Company Overview
- 9.6.3. Product Portfolio
- 9.6.4. Business Strategies
9.7. CVRx, Inc.
- 9.7.1. Quick Facts
- 9.7.2. Company Overview
- 9.7.3. Product Portfolio
- 9.7.4. Business Strategies
9.8. Imec
- 9.8.1. Quick Facts
- 9.8.2. Company Overview
- 9.8.3. Product Portfolio
- 9.8.4. Business Strategies
9.9. Kernel
- 9.9.1. Quick Facts
- 9.9.2. Company Overview
- 9.9.3. Product Portfolio
- 9.9.4. Business Strategies
9.10. LivaNova PLC
- 9.10.1. Quick Facts
- 9.10.2. Company Overview
- 9.10.3. Product Portfolio
- 9.10.4. Business Strategies
9.11. Neurable
- 9.11.1. Quick Facts
- 9.11.2. Company Overview
- 9.11.3. Product Portfolio
- 9.11.4. Business Strategies
9.12. Neuro France Implants
- 9.12.1. Quick Facts
- 9.12.2. Company Overview
- 9.12.3. Product Portfolio
- 9.12.4. Business Strategies
9.13. Neuromod Devices Ltd.
- 9.13.1. Quick Facts
- 9.13.2. Company Overview
- 9.13.3. Product Portfolio
- 9.13.4. Business Strategies
9.14. NeuroPace Inc.
- 9.14.1. Quick Facts
- 9.14.2. Company Overview
- 9.14.3. Product Portfolio
- 9.14.4. Business Strategies
9.15. Paradromics Inc.
- 9.15.1. Quick Facts
- 9.15.2. Company Overview
- 9.15.3. Product Portfolio
- 9.15.4. Business Strategies
9.16. Phagenesis Ltd.
- 9.16.1. Quick Facts
- 9.16.2. Company Overview
- 9.16.3. Product Portfolio
- 9.16.4. Business Strategies
9.17. Renishaw plc
- 9.17.1. Quick Facts
- 9.17.2. Company Overview
- 9.17.3. Product Portfolio
- 9.17.4. Business Strategies
9.18. Stockert GmbH
- 9.18.1. Quick Facts
- 9.18.2. Company Overview
- 9.18.3. Product Portfolio
- 9.18.4. Business Strategies
9.19. Synchron
- 9.19.1. Quick Facts
- 9.19.2. Company Overview
- 9.19.3. Product Portfolio
- 9.19.4. Business Strategies
9.20. Zander Labs
- 9.20.1. Quick Facts
- 9.20.2. Company Overview
- 9.20.3. Product Portfolio
- 9.20.4. Business Strategies